Nivocad (nivolumab biosimilar) / Biocad - LARVOL DELTA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (clinicaltrials.gov) - P=N/A | N=7458 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Dec 2025

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CTLA4 • PD-1 • PD-L1

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Sep 2027

Trial completion date • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor

ETCTN-9844: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - P1 | N=57 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Sep 2027

Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Jun 2028 ➔ Jun 2033

Trial completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

А phase III randomized study comparing BCD-263, a nivolumab biosimilar and reference nivolumab in patients with advanced cutaneous melanoma (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • TNFRSF10C

A051901: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov) - P1 | N=47 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: Sep 2026 ➔ Dec 2026

Trial initiation date • Basal Cell Carcinoma • Cervical Cancer • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hodgkin Lymphoma • Kaposi Sarcoma • Lung Cancer • Lymphoma • Merkel Cell Carcinoma • Mucosal Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • Urothelial Cancer • ALK • EGFR • MSI • PD-L1 • ROS1

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=226 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Mar 2029 ➔ Mar 2034

Trial completion date • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • IL2

ARAR2221: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov) - P2 | N=82 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

dMMR • IO biomarker • MSI-H • pMMR • Trial completion date • Carcinosarcoma • Endometrial Cancer • Oncology • Sarcoma • Solid Tumor • Uterine Cancer

NCI-2016-01300: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Checkpoint inhibition • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov) - P2/3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Aug 2027 | Trial primary completion date: Jul 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov) - P2 | N=101 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Jul 2027 | Trial primary completion date: Sep 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • PD-L1

Russia’s Biocad wins approval for Nivocad, biosimilar to BMS’s Opdivo (GxP News) - "The new drug is indicated for the same uses as the original."

Approval • Colorectal Cancer • Esophageal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hodgkin Lymphoma • Melanoma • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Urothelial Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov) - P2 | N=314 | Recruiting | Sponsor: National Cancer Institute (NCI) | N=224 ➔ 314

Enrollment change • Bladder Cancer • Clear Cell Renal Cell Carcinoma • Endocrine Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Medullary Carcinoma • Lung Cancer • Nasopharyngeal Carcinoma • Neuroendocrine Tumor • Oncology • Penile Cancer • Prostate Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Testicular Cancer • Urethral Cancer • Urothelial Cancer • CD4 • PD-L1

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Apr 2030 ➔ Jun 2029 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov) - P2 | N=314 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Bladder Cancer • Clear Cell Renal Cell Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Kidney Medullary Carcinoma • Large Cell Carcinoma • Lung Cancer • Nasopharyngeal Carcinoma • Neuroendocrine Tumor • Oncology • Papillary Renal Cell Carcinoma • Penile Cancer • Prostate Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Testicular Cancer • Urethral Cancer • Urothelial Cancer • CD4 • PD-L1

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov) - P3 | N=718 | Recruiting | Sponsor: SWOG Cancer Research Network | Not yet recruiting ➔ Recruiting

Enrollment open • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study (clinicaltrials.gov) - P3 | N=1190 | Recruiting | Sponsor: National Cancer Institute (NCI) | Phase classification: P2/3 ➔ P3

Phase classification • Tumor cell • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=184 | Recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Recruiting

Enrollment open • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov) - P2 | N=224 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Feb 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • Bladder Cancer • Clear Cell Renal Cell Carcinoma • Endocrine Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Medullary Carcinoma • Lung Cancer • Nasopharyngeal Carcinoma • Neuroendocrine Tumor • Oncology • Penile Cancer • Prostate Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Testicular Cancer • Urethral Cancer • Urothelial Cancer • CD4 • PD-L1

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study (clinicaltrials.gov) - P2/3 | N=1190 | Recruiting | Sponsor: National Cancer Institute (NCI) | Phase classification: P3 ➔ P2/3

Phase classification • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study (clinicaltrials.gov) - P2/3 | N=1190 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2026 ➔ Sep 2030 | Trial primary completion date: Apr 2026 ➔ Sep 2030

Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov) - P2 | N=50 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1